Preliminary study on the sensitivity test of Acinetobacter baumannii in vitro by flow cytometry / 国际检验医学杂志

Objective To investigate the clinical application significance of flow cytofluroometric(FCM ) antibiotic susceptibility test for A .baumannii in vitro .Methods The sensitivity to Ampicillin/Sulbactam ,Levofloxacin ,Meropenem ,Cefotaxime of an Esch‐erichia coli standard strain and 66 isolates of A .baumannii were tested with FCM by using propidium iodide as a fluorescent probe . The survival rates of the bacteria in the culture after treatment with different dosages of the antibiotics were determined according to the fluorescence strength .The MIC value of the antibiotics against the 66 strains were judged with FCM ,compared with microdi‐lution and VITEK methods .Results The antibiotic resistant strains number of sultamicillin ,levofloxacin ,meropenem and cefo‐taxime sodium were 35 ,30 ,13 and 38 respectively in flow cytofluorometric antibiotic sensitivity test(FCST) of 66 strains of A .bau‐mannii .There was no significant difference(P>0 .05) compared with the antibiotic susceptibility results by the methods of VITEK instrument and microdilution by measuring with χ2 test respectively .Conclusion The established method of FCST for A .baumannii is suitable for dectecting bacterial drug‐sensitivity ,which is more rapid ,accurate and objective .

Eficacia de dosis única endovenosa de sultamicilina (unasyn IV) como antibioticoterapia profiláctica antes de la cirugía del tercer molar / Effectiveness of single dose of intravenous sultamicillin as prophylaxis antibotic therapy before the third molar surgery

El uso racional de los antimicrobianos es imperante para evitar la resistencia bacteriana, sin embargo, la antibioticoterapia profiláctica en la cirugía del tercer molar sigue siendo un tema controversial en cuanto a su administración y duración del tratamiento. Basándonos en las recomendaciones de la Sociedad Americana de Cardiología para profilaxis de endocarditis bacteriana, cuyo protocolo es una dosis única previa a la cirugía, nos planteamos el siguiente estudio, cuyo objetivo fue la evaluación clínica del uso endovenoso de una dosis única de SULTAMICILINA (UNASYNR IV) como antibioticoterapia profiláctica en la cirugía de terceros molares. Al efecto se seleccionó una muestra de 45 pacientes, masculinos y femeninos, de la sala clínica del Post Grado de Cirugía Bucal de la Facultad de Odontología de la Universidad Central de Venezuela con indicación de extracción de los terceros molares retenidos, quienes firmaron el consentimiento informado y fueron organizados en tres grupos de 15 pacientes bajo el siguiente esquema: Grupo A, al cual se le administró 1,5 g de UnasynR IV, Grupo B cuyos integrantes recibieron 3g de UnasynR IV y, por último, Grupo C, el cual fue el grupo control al que se le administró 500 mg de Amoxicilina por vía oral. Se realizaron 4 controles: a las 0 horas, a las 48 horas, 72 horas y a los 7 días. Los resultados obtenidos demostraron que todas las dosis fueron efectivas y no existió diferencia significativa entre los tres grupos estudiados (p>0,05). Por tanto, se recomienda el esquema de 1,5 gramos de Sultamicilina

The rational use of antimicrobials is imperative to avoid bacterial resistance; however, antibiotic prophylaxis in third molar surgery remains a controversial issue in terms of administration and duration of treatment. Based on the recommendations of the American Heart Association for prophylaxis of bacterial endocarditic, whose protocol is a single dose prior to surgery, we considered the following clinical trial aiming at clinical evaluation of intravenous use of a single dose of Sultamicillin as prophylactic antibiotic therapy in patients undergoing third molar surgery. For the development of this research, we used a sample of 45 male and female patients that attended to the Oral Surgery Graduate School of Dentistry, in the Central University of Venezuela, indicating extraction of the third molars, who signed informed consent and were organized into three groups of 15 patients under the following scheme: Group A which was administered with 1.5 g of Sultamicillin intravenously, Group B witch received 3 g of Sultamicillin intravenously, and finally Group C which was the control group who were given Amoxicillin 500 mg orally. Four controls were performed: at 0 hours, 48 hours, 72 hours and 7 days by direct clinical evaluation by the operator, where we evaluated the presence or absence of purulent exudate, oral hygiene, presence and degree of pain according to the Visual Analog Scale (VAS). Results showed the effectiveness of all doses and no significant difference between the three groups by Willcoxon (p> 0.05). Therefore we recommend the use of Sultamicillin 1,5 grams intravenously

Comparación de la biodisponibilidad de un producto test conteniendo sultamicilia comprimidos de 375 mg de liberación inmediata de laboratorios Genven (Leti, S. A. V.) contra la sultamicilina de referencia (unasyn ®) tabletas de 375 mg de laboratorios Pfizer, luego de administrar una dosis única en voluntarios sanos / Comparison of the bioavailability of a test product containing sultamicillin tablets of 375 mg immediate release laboratorios Genven (Leti, SAV) against sultamicillin reference (Unasyn ®) 375 mg tablets of Pfizer, after single dose administration in healthy volunteers

El objetivo del estudio es evaluar la biodisponibilidad comparada entre dos formulaciones de liberación inmediata de Sultamicilina 375 mg, luego de una administración única, en un mismo grupo de voluntarios sanos. El estudio se realizó en 12 voluntarios sanos de ambos sexos. Los voluntarios recibieron de acuerdo al esquema asignado por la aleatorización y en dos períodos, una dosis única por vía oral de un comprimido de una formulación conteniendo 375 mg de Sultamicilina de Laboratorios Genven (Leti, S.A.V.), o una tableta del producto de referencia Unasyn®, de Laboratorios Pfizer. La administración se realizó en ayuno de 10 horas de duración y se mantuvo por dos horas después de suministrado el fármaco. Entre ambos períodos se realizó un lavado de tres días. Los voluntarios que recibieron el producto test en el primer período recibieron el producto de referencia y viceversa. Durante cada período del estudio se obtuvieron doce muestras de sangre: antes de la dosis (tiempo cero), a los 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 y 360 minutos. Para ampicilina las variables farmacocinéticas fueron: formulación test Cmax 2.488.52+/-730.65 ng/mL y para ampicilina referencia 2.392,78+/-931,12 ng/mL; para las AUC0-6 fueron de 169.495,82+/-57506,34 ng/mL/h para la formulación test y de 178.688,42+/-85.534,02 ng/mL/h para la formulación de referencia, para la AUC0-∞ los valores resultante fueron 171.230+/-57.601,31 ng/mL/h para la formulación test y de 179.553,73+/-85.966 ng/mL/h para la formulación de referencia. Para el sulbactam las variables farmacocinéticas fueron: formulación test, Cmax: 2.176,66+/-711,57 ng/mL y para la referencia 2.097,70+/-486,17 ng/mL; las AUC0-6 fueron de 175.924,62+/-45.652,94 ng/mL/h para la formulación test y de 186.342,94+/-47.001,80 ng/mL/h para la formulación de referencia, para la AUC0-∞ los valores resultantes...

Objective: Evaluated the comparative bioavailability of two formulations of immediate release 375 mg Sultamicillin after a single administration in the same group of healthy volunteers.Methods: The study was conducted in 12 healthy volunteers of both sexes. The volunteers were assigned according to the randomization scheme and two periods, a single oral dose of one tablet of a formulation containing 375 mg of Sultamicillin Genven (Leti, S.A.V.) Laboratories, or the reference product Unasyn®, Pfizer Laboratories. The administration was carried out in fast of 10 hours and continued for two hours after administeringthe drug. Between the two periods was a washout period of three days. Volunteers who received the test product in the first period will receive the reference product and vice versa. During each period of twelve samples were obtained from blood: pre-dose (time zero) 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 minutes.Results: For ampicillin pharmacokinetic parameters were Cmax test formulation � 2.488.52+/-730.65 ng/mLand referenceformulation 2.392,78+/-931.12 ng/mL; for AUC0-6 were 169.495,82+/-57.506,34 ng/mL/h for the test formulation and � 178.688,42+/-85.534,02 ng/mL/hfor the reference formulation,for the AUC0-∞ the resulting values were 171.230+/-57.601,31 ng/mL/h for the test formulation and 179.553,73+/-85.966 ng/mL/h for the reference formulation.For sulbactam pharmacokinetic parameters were: Cmax: test 2.176,66+/-711.57 ng/mL and reference 2.097,70+/-486.17 ng/mL; the AUC0-6 were 175.924,62+/-45.652,94 ng/mL/h for the test formulation and 186.342.94+/-47.001,80 ng/mL/h for the reference formulation, for the AUC0-∞ the resultingvalues were 176.900.54+/-45.843,65 ng/mL/hto formulationtest and 187.399,88+/-47.487,22 ng/mL/h for the reference formulation...

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus

This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinipristin-dalfopristin against seven hetero-VISA strains and two methicillin-resistant S. aureus strains were evaluated by the time-kill assay. The combinations of arbekacin with vancomycin, teicoplanin, or ampicillinsulbactam showed the synergistic interaction against hetero-VISA strains. Data suggest that these arbekacin-based combination regimens may be useful candidates for treatment options of hetero-VISA infections.